Search

A recent study conducted at Sun Yat-sen University in Guangzhou, China, explored the effectiveness and safety of different dosage forms of gonadotropin-releasing hormone (GnRH) agonist in premenopausal hormone receptor-positive breast cancer patients. The study included 1109 patients who were treated with GnRH agonist plus selective estrogen receptor modulator or aromatase inhibitor. The results showed that both the 1-month and 3-month GnRH agonist regimens achieved more than 90% estradiol (E2) inhibition within 24 months, confirming the noninferiority of the 3-month regimen. The study concluded that the ovarian function suppression with the 3-month GnRH agonist was not inferior to that with the 1-month regimen, regardless of age or combination with other medications. [Extracted from the article]